Urology News and Research

Latest Urology News and Research

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan plc, a leading global pharmaceutical company, today announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.

4 Nov 2015

UCLA study finds cost variation across entire care process for low-risk prostate cancer

Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer - from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing. And they found a wide variation in costs for the various available treatments that remained consistent over a 12-year period, indicating a better method to monitor costs could save valuable healthcare dollars, said study first author Dr. Aaron Laviana, a fifth year urology resident.

3 Nov 2015

Hitachi presents new ultrasound platform at United European Gastroenterology Week

Ultrasound diagnosis is an indispensable tool for a variety of clinical applications and users have high expectations that challenge modern, powerful ultrasound platforms. With the new brand ARIETTA , Hitachi presents a new solution that meets these demands.

26 Oct 2015

ESPU, ICCS launch World Bedwetting Day to raise awareness among children and families

The International Children’s Continence Society and the European Society for Paediatric Urology announced today the launch of World Bedwetting Day at the 26th ESPU Congress in Prague.

20 Oct 2015

Allergan completes acquisition of AqueSys

Allergan plc, a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma.

19 Oct 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

ADMT announces filing of FDA 510(k) application for Angiodroid The CO2 Injector for Angiography

ADM Tronics Unlimited, Inc. has announced that a Premarket Notification 510(k) application has been filed with the US Food and Drug Administration for Angiodroid The CO2 Injector for Angiography (the "Angiodroid Injector") by Angiodroid America, Inc., a subsidiary of Angiodroid, Srl, in affiliation with Triotech Ventures and ADMT, as previously announced.

15 Oct 2015

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

The US Food and Drug Administration has approved SonaCare Medical's Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables treatment of organ-confined prostate disease while preserving surrounding healthy tissue, without radiation or surgery.

14 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Recipients of 2015 Ferring Innovation Grants announced

Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. This global program awards each recipient $50,000 to support research in the fields of Reproductive Health, Gastroenterology and/or Urology.

7 Oct 2015

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe.

From Oxford Gene Technology 6 Oct 2015

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Keck School of Medicine of USC researcher wins first Hearst Fellowship

Albert D. Kim, Ph.D., a postdoctoral fellow at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California, is the first Keck School of Medicine of USC researcher to win a Hearst Fellowship for his work investigating how to turn stem cells into nephrons, the functional units of the kidney.

26 Sep 2015

TIS physicians selected as recipients of D Magazine 2015 Best Doctors in Dallas

More than 30 physicians credentialed to practice at Texas Institute for Surgery at Texas Heath Presbyterian Dallas (TIS) are recognized by D Magazine in its October issue, Best Doctors 2015.

26 Sep 2015

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

Allergan plc, a leading global pharmaceutical company, today announced that it has launched a generic version of Janssen's INVEGA (paliperidone extended-release tablets) in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.

25 Sep 2015

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

Prashant Mahajan, M.D., professor of Pediatrics and Emergency Medicine, chief of the Division of Emergency Medicine in the Department of Pediatrics at Wayne State University and Children's Hospital of Michigan, has been awarded a five-year, $5.76 million grant (1R01HD085233) by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health.

23 Sep 2015

Urology News and Research

Latest Urology News and Research

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

UCLA study finds cost variation across entire care process for low-risk prostate cancer

Hitachi presents new ultrasound platform at United European Gastroenterology Week

ESPU, ICCS launch World Bedwetting Day to raise awareness among children and families

Allergan completes acquisition of AqueSys

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

ADMT announces filing of FDA 510(k) application for Angiodroid The CO2 Injector for Angiography

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Recipients of 2015 Ferring Innovation Grants announced

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Keck School of Medicine of USC researcher wins first Hearst Fellowship

TIS physicians selected as recipients of D Magazine 2015 Best Doctors in Dallas

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in